<< Back To Home

CSU 69/2010: NEONATAL MORTALITY REDUCTION AND 'KANGAROO MOTHER CARE'

Friday, 11th of June 2010 Print
CSU 69/2010: NEONATAL MORTALITY REDUCTION AND 'KANGAROO MOTHER CARE'
  
The achievement of MDG4 will, in most countries, require a more aggressive approach to neonatal mortality. In this review by Joy Lawn and colleagues, the 'kangaroo mother care' approach, using thermal care through skin to skin contact, support for exclusive breastfeeding, and early recognition/response to illness, is found to be effective in mortality reduction.
 
'KMC substantially reduces neonatal mortality amongst preterm babies (birth weight <2000 g) in hospital, and is highly effective in reducing severe morbidity, particularly from infection. However, KMC remains unavailable at-scale in most low-income countries.'
 
Full text is at http://ije.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=20348117
 
Good reading.
 
BD
 

Warning: The NCBI web site requires JavaScript to function. more...

'Kangaroo mother care' to prevent neonatal deaths due to preterm birth complications.

Lawn JE, Mwansa-Kambafwile J, Horta BL, Barros FC, Cousens S.

Saving Newborn Lives/Save the Children-USA, Cape Town, South Africa. joylawn@yahoo.co.uk

Abstract

BACKGROUND: 'Kangaroo mother care' (KMC) includes thermal care through continuous skin-to-skin contact, support for exclusive breastfeeding or other appropriate feeding, and early recognition/response to illness. Whilst increasingly accepted in both high- and low-income countries, a Cochrane review (2003) did not find evidence of KMC's mortality benefit, and did not report neonatal-specific data.

OBJECTIVES: The objectives of this study were to review the evidence, and estimate the effect of KMC on neonatal mortality due to complications of preterm birth.

METHODS: We conducted systematic reviews. Standardized abstraction tables were used and study quality assessed by adapted GRADE methodology. Meta-analyses were undertaken.

RESULTS: We identified 15 studies reporting mortality and/or morbidity outcomes including nine randomized controlled trials (RCTs) and six observational studies all from low- or middle-income settings. Except one, all were hospital-based and included only babies of birth-weight <2000 g (assumed preterm). The one community-based trial had missing birthweight data, as well as other limitations and was excluded. Neonatal-specific data were supplied by two authors. Meta-analysis of three RCTs commencing KMC in the first week of life showed a significant reduction in neonatal mortality [relative risk (RR) 0.49, 95% confidence interval (CI) 0.29-0.82] compared with standard care. A meta-analysis of three observational studies also suggested significant mortality benefit (RR 0.68, 95% CI 0.58-0.79). Five RCTs suggested significant reductions in serious morbidity for babies <2000 g (RR 0.34, 95% CI 0.17-0.65).

CONCLUSION: This is the first published meta-analysis showing that KMC substantially reduces neonatal mortality amongst preterm babies (birth weight <2000 g) in hospital, and is highly effective in reducing severe morbidity, particularly from infection. However, KMC remains unavailable at-scale in most low-income countries.

40916180